HRP20160328T1 - Tritokvalin za uporabu u liječenju cistične fibroze - Google Patents

Tritokvalin za uporabu u liječenju cistične fibroze Download PDF

Info

Publication number
HRP20160328T1
HRP20160328T1 HRP20160328TT HRP20160328T HRP20160328T1 HR P20160328 T1 HRP20160328 T1 HR P20160328T1 HR P20160328T T HRP20160328T T HR P20160328TT HR P20160328 T HRP20160328 T HR P20160328T HR P20160328 T1 HRP20160328 T1 HR P20160328T1
Authority
HR
Croatia
Prior art keywords
tritoqualine
cystic fibrosis
use according
day
complications
Prior art date
Application number
HRP20160328TT
Other languages
English (en)
Inventor
Dominique Costantini
Original Assignee
Orphan Synergy Europe - Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Synergy Europe - Pharma filed Critical Orphan Synergy Europe - Pharma
Publication of HRP20160328T1 publication Critical patent/HRP20160328T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (8)

1. Tritokvalin za uporabu u liječenju cistične fibroze ili barem jedne od komplikacija povezanih sa cističnom fibrozom.
2. Tritokvalin za uporabu prema zahtjevu 1, gdje se komplikacije cistične fibroze izabiru između infekcije ili upalnih poremećaja.
3. Tritokvalin za uporabu prema zahtjevu 1 ili 2, gdje se komplikacije cistične fibroze izabiru između infekcije ili upalnih poremećaja dišnog sustava, gušterače, probavnog sustava, žlijezda znojnica ili drugih egzokrinih tkiva.
4. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-3, gdje se komplikacije cistične fibroze izabiru između teške kronične bolesti pluća, insuficijencije gušterače, nazalne polipoze, pansinusitisa, kronične dijareje, pankreatitisa, ciroze ili drugih oblika disfunkcije jetre, bolesti sinusa, dijabetesa ili hepatobilijarnih problema, specifičnije fokalne bilijarne ciroze, bilijarne opstrukcije i progresivne periportalne fibroze.
5. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-4, u liječenju bolesti cistične fibroze i/ili bilo koje od komplikacija povezanih s dišnim putovima ili nazalnim komplikacijama.
6. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-5, gdje se tritokvalin primjenjuje subjektu u dozi od 1 mg-4 g/dan.
7. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-6, gdje se tritokvalin primjenjuje subjektu u dozi od 1, 5, 10, 20, 30, 50, 100, 200, 300, 400, 500, ili 600 mg/dan.
8. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-6, gdje se tritokvalin primjenjuje subjektu u dozi od 1 g/dan, 2 g/dan, 3 g/dan ili 4 g/dan.
HRP20160328TT 2012-04-30 2016-04-01 Tritokvalin za uporabu u liječenju cistične fibroze HRP20160328T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305487.6A EP2659890A1 (en) 2012-04-30 2012-04-30 Methods and compositions for the treatment of fibrosis
PCT/EP2013/058158 WO2013164204A1 (en) 2012-04-30 2013-04-19 Tritoqualine for use in the treatment of cystic fibrosis
EP13718559.1A EP2844253B1 (en) 2012-04-30 2013-04-19 Tritoqualine for use in the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
HRP20160328T1 true HRP20160328T1 (hr) 2016-06-03

Family

ID=48184183

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160328TT HRP20160328T1 (hr) 2012-04-30 2016-04-01 Tritokvalin za uporabu u liječenju cistične fibroze

Country Status (14)

Country Link
US (1) US9301955B2 (hr)
EP (2) EP2659890A1 (hr)
CA (1) CA2871815C (hr)
CY (1) CY1117620T1 (hr)
DK (1) DK2844253T3 (hr)
ES (1) ES2569391T3 (hr)
HR (1) HRP20160328T1 (hr)
HU (1) HUE027353T2 (hr)
IL (1) IL235358B (hr)
PL (1) PL2844253T3 (hr)
RS (1) RS54733B1 (hr)
SI (1) SI2844253T1 (hr)
SM (1) SMT201600102B (hr)
WO (1) WO2013164204A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
FR2990859B1 (fr) * 2012-05-24 2014-05-23 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
JP6963896B2 (ja) * 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Cftr媒介性疾患の処置のための医薬組成物を調製する方法
FR3015977B1 (fr) * 2013-12-30 2016-01-01 Patrice Binay Chlorhydrate de tritoqualine sous forme cristallisee et procede d'obtention
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
FR3048883B1 (fr) * 2016-03-18 2020-10-02 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique
FR3109524B1 (fr) 2020-04-22 2022-04-08 H4 Orphan Pharma Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales.
FR3111071B1 (fr) 2020-06-04 2023-01-13 H4 Orphan Pharma Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003023A1 (en) * 1986-10-31 1988-05-05 Mitsubishi Chemical Industries Limited Drug composition for treating liver diseases and process for its preparation
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
US20070238750A1 (en) 2006-04-07 2007-10-11 Michalis Nicolaou Pure isomers of tritoqualine
EP2559434A3 (en) 2007-02-12 2013-05-29 Mike Nicolaou Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
US20110288114A1 (en) 2008-06-20 2011-11-24 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions

Also Published As

Publication number Publication date
IL235358B (en) 2019-09-26
CA2871815A1 (en) 2013-11-07
RS54733B1 (sr) 2016-10-31
SI2844253T1 (sl) 2016-09-30
DK2844253T3 (en) 2016-04-18
CY1117620T1 (el) 2017-04-26
EP2659890A1 (en) 2013-11-06
PL2844253T3 (pl) 2016-09-30
EP2844253A1 (en) 2015-03-11
US9301955B2 (en) 2016-04-05
SMT201600102B (it) 2016-07-01
ES2569391T3 (es) 2016-05-10
CA2871815C (en) 2019-12-24
WO2013164204A1 (en) 2013-11-07
US20150133487A1 (en) 2015-05-14
IL235358A0 (en) 2014-12-31
EP2844253B1 (en) 2016-03-23
HUE027353T2 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
HRP20160328T1 (hr) Tritokvalin za uporabu u liječenju cistične fibroze
PH12018500765B1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
WO2018132432A8 (en) Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
WO2009064460A3 (en) Gastrointestinal delivery systems
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
MX2013013503A (es) Composiciones de vancomicina en polvo seco y metodos asociados.
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
HRP20200661T1 (hr) Razine ceramida u liječenju i prevenciji infekcija
HK1137807A1 (en) Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
MY162339A (en) Nanoparticles loaded with chemotherapeutic antitumoral drug
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
MX340138B (es) Tratamiento de trastornos relacionados con la discinesia.
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2014169094A3 (en) Nhe3-binding compounds and methods for inhibiting phosphate transport
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
WO2011055383A3 (en) Intranasal delivery to improve the performance of children suffering from dyslexia
MX2009008548A (es) Formulaciones de olopatadina para administracion nasal topica.